



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/725,969 12/02/2003		Paul B. Fisher	A34587 C-PCT-USA-I 070050	4037	
21003	7590 01/24	;	EXAMINER		
BAKER &	BOTTS ELLER PLAZA	THOMAS, DAVID C			
	L NY 10112	ART UNIT	PAPER NUMBER		
	,	1637			
		DATE MAILED: 01/24/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No. Applicant(s)							
Office Action Summary			10/725,969	9	FISHER, PAUL I	FISHER, PAUL B.			
			Examiner		Art Unit				
			David C. Ti	nomas	1637				
Period fo	The MAILING DATE of this communic or Reply	ation app	ears on the	cover sheet with th	ne correspondence a	ddress			
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MAnsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this community of the reply is specified above, the maximum stature to reply within the set or extended period for reply were ply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ILING DA f 37 CFR 1.13 nication. utory period w ill, by statute,	ATE OF THE 66(a). In no ever will apply and will cause the appli	IS COMMUNICAT nt, however, may a reply b expire SIX (6) MONTHS cation to become ABANDO	ION. be timely filed from the mailing date of this of the control of the contro	,			
Status									
1)⊠	Responsive to communication(s) filed	on 18 Ma	arch 2004						
·	This action is FINAL . 2b)⊠ This action is non-final.								
3)	·								
٠,٠	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims		•		,				
-	Claim(s) <u>1-40</u> is/are pending in the application. 4a) Of the above claim(s) <u>1-19 and 21-38</u> is/are withdrawn from consideration.								
	• • • • • • • • • • • • • • • • • • • •								
	Claim(s) is/are allowed.								
7)	Claim(s) is/are rejected.								
,	☐ Claim(s) is/are objected to. ☑ Claim(s) <u>20 and 39-40</u> are subject to restriction and/or election requirement.								
	_	i estriction	and/or elec	zion requirement.					
Applicati	on Papers								
9)[The specification is objected to by the	Examiner	r.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11)	The oath or declaration is objected to l	by the Exa	aminer. Not	e the attached Off	fice Action or form P	TO-152.			
Priority ι	ınder 35 U.S.C. § 119								
a)[Acknowledgment is made of a claim for All b) Some * c) None of: 1. Certified copies of the priority d. 2. Certified copies of the priority d. 3. Copies of the certified copies of application from the International cee the attached detailed Office action	ocuments ocuments f the priori al Bureau	s have been s have been ity documen (PCT Rule	n received. n received in Applionts have been received 17.2(a)).	cation No eived in this Nationa	l Stage			
2)	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTonation Disclosure Statement(s) (PTO-1449 or Provo(s)/Mail Date			4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:		O-152)			

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 20 and 39, drawn to nucleic acids, classified in class 536, subclass
 23.1.
 - II. Claim 40, drawn to polypeptides, classified in class 530, subclass 350.
 The inventions are distinct, each from the other because of the following reasons:
- 2. Inventions I and II are patentably distinct products.

The polynucleotide of Group I and polypeptide of Group II are patentably distinct inventions for the following reasons. Polypeptides, which are composed of amino acids, and polynucleotides, which are composed of purine and pyrimidine units, are structurally distinct molecules; any relationship between a polynucleotide and polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, some polynucleotides of Group I do not necessarily encode a polypeptide of Group II. Furthermore, the information provided by the polynucleotides of Group I can be used to make a materially different polypeptide than that of Group II. In addition, while a polypeptide of Group II can made by methods using some, but not all, of the polynucleotides that fall within the scope of Group I, it can also be recovered from a natural source using biochemical means. For instance, the polypeptide can be isolated using affinity chromatography. For these reasons, the inventions of Groups I and II are patentably distinct.

Application/Control Number: 10/725,969 Page 3

Art Unit: 1637

Furthermore, searching the inventions of Groups I and II together would impose a serious search burden. In the instant case, the search of the polypeptides and the polynucleotides are not coextensive. The inventions of Groups I and II have a separate status in the art as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to polypeptides which would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers which had no knowledge of the polypeptide but spoke to the gene. Searching, therefore is not coextensive.

3. This application contains claims directed to 23 patentably distinct inventions, specifically, the 18 individual nucleic acid sequences indicated in claim 20 and the 5 individual polypeptide sequences indicated in claim 40. After election of one of the Groups above, Applicant is required to also elect one of the sequences from the elected Group. This is not a species election. Applicant will be required to cancel non-elected subject matter upon indication of allowable subject matter.

Applicant is also requested to amend the claims so that the elected sequence is designated with a SEQ ID. NO. corresponding to the same sequence in the Sequence Listing.

Application/Control Number: 10/725,969 Page 4

Art Unit: 1637

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David C. Thomas whose telephone number is 571-272-3320. The examiner can normally be reached on 5 days, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David C. Thomas
Patent Examiner
Art Unit 1637

JEFFREY FREDMAN
PRIMARY EXAMINER